Evidence map›Paper›PMID 34046448›Full record

ArticleInorganics2020

Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.

Lauren Fernandez-Vega, Valeria A Ruiz Silva, Tania M Domínguez-González, Sebastián Claudio-Betancourt, Rafael E Toro-Maldonado, Luisa C Capre Maso, Karina Sanabria Ortiz, Jean A Pérez-Verdejo, Janeishly Román González, Grecia T Rosado-Fraticelli and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inorganics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Synthesis of asymmetrical diaminobis(alkoxo)-bisphenol compounds and their CDalton transactions (Cambridge, England : 2003) · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lauren Fernandez-VegaDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Valeria A Ruiz SilvaDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Tania M Domínguez-GonzálezDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Sebastián Claudio-BetancourtDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Rafael E Toro-MaldonadoDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Luisa C Capre MasoDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Karina Sanabria OrtizDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Jean A Pérez-VerdejoDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Janeishly Román GonzálezDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Grecia T Rosado-FraticelliDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Fabiola Pagán MeléndezDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Fabiola M Betancourt SantiagoDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Daniel A Rivera-RiveraDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Carlos Martínez NavarroDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Andrea C Bruno ChardónDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Axel O VeraDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.
Arthur D TinocoDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, USA.

Funding

Upgrade Laboratories Facilities at UPR-Rio PiedrasR25GM061151 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2001 to 2023
$32.5M
RIO PIEDRAS MARC U*STAR DEVELOPMENT PROGRAMT34GM007821 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 1985 to 2020
$20.3M
Neuroscience Research Opportunities to Increase Diversity (NeuroID)R25NS080687 · NINDS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI GARCIA-ARRARAS, JOSE E, MALDONADO-VLAAR, CARMEN SARA · 2012 to 2024
$5.3M
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer DSC1CA190504 · NCI · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI TINOCO, ARTHUR DAVID · 2014 to 2017
$1.4M
NCI NIH HHS SC1 CA190504NIGMS NIH HHS R25 GM061151NIGMS NIH HHS T34 GM007821NINDS NIH HHS R25 NS080687
6 · The paper itself

Abstract

Over time platinum-based anticancer drugs have dominated the market, but their side effects significantly impact the quality of life of patients. Alternative treatments are being developed all over the world. The titanocene and auranofin families of compounds, discovered through an empirical search for other metal-based therapeutics, hold tremendous promise to improve the outcomes of cancer treatment. Herein we present a historical perspective of these compounds and review current efforts focused on the evolution of their ligands to improve their physiological solution stability, cancer selectivity, and antiproliferative performance, guided by a clear understanding of the coordination chemistry and aqueous speciation of the metal ions, of the cytotoxic mechanism of action of the compounds, and the external factors that limit their therapeutic potential. Newer members of these families of compounds and their combination in novel bimetallic complexes are the result of years of scientific research. We believe that this review can have a positive impact in the development and understanding of the metal-based drugs of gold, titanium, and beyond.

Indexed as

anticancer metallodrugsauranofinfunctionalized ligandsligand designtitanocene

Identifiers

PMID34046448
PMCPMC8152503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.